Our Services
Medical Information
Helpful Resources
Published on: 10/26/2026
Zetia is the brand name for ezetimibe, a non-statin cholesterol medication that works in the small intestine by blocking the NPC1L1 transporter, which reduces how much dietary and biliary cholesterol your body absorbs. Statins work differently, lowering LDL by inhibiting the liver enzyme HMG-CoA reductase and slowing cholesterol production at the source. Because the two mechanisms are separate, Zetia can be used on its own for people who cannot tolerate statins, or added to a statin for extra LDL reduction of roughly 15 to 25 percent. There are important differences in side effects, LDL-lowering strength, and proven cardiovascular benefit to weigh, so see below for the complete details before assuming one option fits your situation.
If high cholesterol comes with symptoms like muscle aches, fatigue, chest discomfort, or stomach upset, it helps to know whether your medication, another condition, or something unrelated is the likely cause, and a free, instant, online symptom check can help you sort through the possibilities in minutes and walk into your next appointment with clearer questions.
Last reviewed for medical accuracy: 10/22/2026
Zetia (generic name: ezetimibe) is a prescription medication used to lower cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol. Unlike statins, which reduce cholesterol production in the liver, Zetia works by blocking cholesterol absorption in the small intestine. This difference in action makes Zetia a useful option for people who can’t tolerate statins or who need additional LDL-lowering on top of statin therapy.
Zetia (ezetimibe) is part of a class of drugs called cholesterol absorption inhibitors. It’s approved by the U.S. Food and Drug Administration (FDA) to help:
Key points about Zetia:
If you’re unsure whether you need cholesterol testing or have worrisome symptoms, you might try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Zetia targets a protein called NPC1L1 (Niemann-Pick C1-like 1) in the lining of the small intestine. This protein is responsible for transporting cholesterol from the food you eat into your bloodstream.
Blocking absorption
Effect on liver cholesterol
No impact on cholesterol production
Statins are the most prescribed cholesterol-lowering drugs. Their main effects include:
Common statins include atorvastatin, simvastatin, and rosuvastatin.
| Feature | Zetia (Ezetimibe) | Statins |
|---|---|---|
| Primary action | Blocks intestinal cholesterol absorption (NPC1L1) | Inhibits liver cholesterol synthesis (HMG-CoA reductase) |
| Site of activity | Small intestine | Liver |
| LDL reduction alone | 15–20% | 20–55% (dose-dependent) |
| Common side effects | Headache, diarrhea, back pain | Muscle aches, liver enzyme changes |
| Drug interactions | Relatively few | More potential (e.g., with grapefruit, certain antibiotics) |
| Use in statin intolerance | Yes (monotherapy option) | Not applicable |
Zetia is generally well-tolerated. Common side effects include:
Rare but serious reactions can occur. Contact your doctor if you experience:
You and your healthcare provider may consider Zetia if you:
In all cases, Zetia is prescribed along with diet, exercise, and lifestyle changes.
Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance on whether your symptoms need medical attention.
Even with medication, healthy habits boost your results:
Always discuss changes in your health or medication with your healthcare provider. Seek immediate medical attention if you experience:
This information is not a substitute for professional medical advice. If you have serious or life-threatening symptoms, speak to a doctor right away.
For personalized advice or if you aren’t sure about your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. Always follow up with your healthcare provider for serious concerns or before making changes to your treatment plan.
(References)
* Meng CQ. Ezetimibe (Schering-Plough). Curr Opin Investig Drugs. 2001 Mar;2(3):389-92. PMID: 11575710.
* Filippatos TD, Elisaf MS. Statin-Ezetimibe Combination Therapy In Diabetic Individuals. Angiology. 2016 Jul;67(6):507-9. doi: 10.1177/0003319715598887. Epub 2015 Aug 14. PMID: 26275885.
* Lüscher TF. Risk assessement and its management: from SCORE to statins, ezetimibe to PCSK inhibitors. Eur Heart J. 2017 Aug 1;38(29):2233-2236. doi: 10.1093/eurheartj/ehx435. PMID: 28810720.
* Karásek D. [Combined lipid-lowering therapy]. Vnitr Lek. 2019 Winter;64(12):1177-1184. PMID: 30704254.
* Jia X, Lorenz P, Ballantyne CM. Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):32-38. doi: 10.14797/mdcj-15-1-32. PMID: 31049147; PMCID: PMC6489602.
* Khan SU, Yedlapati SH, Lone AN, Hao Q, Guyatt G, Delvaux N, Bekkering GET, Vandvik PO, Riaz IB, Li S, Aertgeerts B, Rodondi N. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022 May 4;377:e069116. doi: 10.1136/bmj-2021-069116. Epub 2022 May 4. PMID: 35508321.
* Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, Heo JH, Rha SW, Cho YH, Lee SJ, Ahn CM, Kim JS, Ko YG, Choi D, Jang Y, Hong MK, RACING investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18. PMID: 35863366.
* Ezetimibe plus moderate-intensity statin versus high-intensity statin. Drug Ther Bull. 2023 Mar;61(3):38. doi: 10.1136/dtb.2023.000008. PMID: 36813278.
* Lee SH, Lee YJ, Heo JH, Hur SH, Choi HH, Kim KJ, Kim JH, Park KH, Lee JH, Choi YJ, Lee SJ, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Jang Y, Kim JS. Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis. J Am Coll Cardiol. 2023 Apr 11;81(14):1339-1349. doi: 10.1016/j.jacc.2023.02.007. PMID: 37019580.
* Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. Am J Cardiovasc Drugs. 2023 Sep;23(5):477-495. doi: 10.1007/s40256-023-00594-5. Epub 2023 Jul 24. PMID: 37486464; PMCID: PMC10462544.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.